Day Two | Advanced/Professional *Sliding Scale*
Details below!
A recording of Day One will be freely available to all registered attendees.
A recording of Day One & Day Two will be available for all paid attendees.
11:00 am - 5:00 pm ET/8:00 am - 2:00 pm PT
Learn from leaders in the psychedelic field on the potential of these medicines to treat a broad spectrum of conditions, including chronic pain, neurodegenerative diseases, and inflammatory disorders. Day One will lay the foundation for understanding how psychedelics can be used to address physical health, extending beyond their well-known applications in mental health.
Welcome, Introduction to Psychedelics for Pain & Physical Conditions
Court Wing, Founder of REMAP Therapeutics, CoFounder of PPA
Best Practices, Harm Reduction, & Pharmaceutical Interactions
Being safe begins with being informed. Learn from CJ Spotswood, PMHNP, author of The Microdosing Guidebook on how psychedelics can be used safely and efficaciously, taking your whole story (pharmaceutical list included) into consideration.
CJ Spotswood, PMHNP, Maine General Health
The Complexity of Chronic Pain & Why Psychedelics Might Help
A recently published paper by this panelist (and colleagues) artfully discusses the "complex system" that pain exists within and why this complexity often leads to poor medical understanding. Psychedelics may address this complexity from a high level, leading to better outcomes.
Maya Armstrong, MD, University of New Mexico Pain Clinic
Clinical Trials of Psychedelics in Headache Disorders
Some of the first research to show the potential of psychedelics to treat pain came from the field of headache conditions. The latest research findings will be presented here.
Emmanuelle Schindler, MD, PhD, Yale University
New Directions in Psychedelic Therapy: Exploring Psilocybin for Post-Treatment Lyme Disease
An exploration of the origins of psychedelics for pain research and a preliminary look at results from the active psilocybin trial for long-Lyme happening in the lab at Johns Hopkins School of Medicine.
Albert Garcia-Romeu, PhD, Johns Hopkins School of Medicine
Patient Perspective: Treating long-COVID with MDMA & Psilocybin
Many patients with long-COVID struggle to find impactful treatment, with symptoms interrupting daily life. Hear directly from MaryAnn, whose unconventional use of psychedelic medicines created lasting relief and a return to normal life.
MaryAnn Welke-Lesange, IT Director, University of Ottowa
Neural Signatures of Pain Patients on Psilocybin
Pain is a full body phenomenon that exists well beyond the location of discomfort. What happens to the way our brains perceive pain when under the influence of psilocybin? A fascinating new study explores this to generate new understanding and potential treatments.
Tess Veuthey, MD, PhD, Stanford School of Medicine
Promise/Peril of Citizen-science in Psychedelic Research for Pain
Anecdotal evidence from brave citizens willing to try psychedelic medicines to treat their conditions often gives science the first signal for new treatments. At what cost? To what potential benefit?
Joanna Kempner, PhD, Rutgers University
Psychedelic Access & Policy
State-by-state, psychedelic policy is coming online, with varying models and rates of success. Learn what the options are, and how to get involved.
Allison Hoots, Esq, Hoots Law & Kevin Lenaburg, Executive Director of PPA
Grow, Source, & Test Your Medicines
Citizen science in action, listen in for resources that thousands of patients have used to safely access these medicines.
Bob Wold, Founder and Executive Director of Clusterbusters, Eileen Brewer, President of Clusterbusters & Kevin Lenaburg, Executive Director of PPA
Patient Perspective: Sacred Plants & Ceremonial Doctoring for Chronic Pain
Explore the exquisite mystery of the Indigenous medicines traditions and how they supported Ariel in relieving years of debilitating pain.
Ariel Clark, Esq, Calyx Law
11:00 am - 6:00 pm ET/8:00 am - 3:00 pm PT
The emergent field of psychedelic medicines for the treatment of pain and physical conditions is growing rapidly. Hear from a broad group of researchers on their latest investigations, findings, and the potential implications. Day Two is paid access only, see ticket information below.
Each session will leave time for 10-15 minutes of Q&A.
Welcome, Introduction, Review of Day One
Court Wing, Founder of REMAP Therapeutics, CoFounder of PPA
LSD-assisted Psychotherapy to Treat Metastatic Cancer-induced Bone Pain
Building on some of the original research into psychedelics for pain, this study will expand and broaden our understanding of how to treat this debilitating side effect of some cancers.
Stephen Ross, MD, NYU, Associate Director of NYU Langone Center for Psychedelic Medicine
Analgesic Effects of Psychedelics: From Surveys to the Lab
Review the robust survey studies coming out of Maastricht University and how they are informing future research in this field.
Mauro Cavarra, Maastrict University, Psychotherapist
Analgesic Potential of Low-Dose Psychedelics & Cathinones for Pain
Not every psychedelic treatment needs to be high-dose. New research shows that smaller doses could be efficacious treatments for some pain conditions.
Dr. Jan Ramaekers, JG, Maastrict University, Professor of Psychopharmacology
Proposed Mechanisms of Psychedelics for Pain & Implications for Patient-Centered Care
Deep dive into what we currently know about the way psychedelics relieve pain and how this could impact future pain treatments.
Joel Castellanos, MD, UCSD Center for Psychedelic Research, Associate Medical Director
The Clusterbusters Survey | Preliminary Data from ~2000 Respondents
Preliminary results from the 2000+ person survey of cluster headache patients.
Mark Burish, MD, PhD UT, Health Houston & Bob Wold, Founder and Executive Director of Clusterbusters
Patient Perspective | Psilocybin for CPRS & Complex Chronic Pain
Years of un-touchable pain led Lynn to ketamine treatments, where she found only minimal relief. One week of intensive psilocybin therapy combined with modulatory techniques led to lasting, deep relief.
Lynn Watkins, Retired USAF JAG Officer
Psychedelics are Powerful Anti-inflammatory Agents
The mechanisms of action of psychedelics are many, and varied. Coming into sharp focus is their incredible potential to modulate inflammation. Learn from the lead researcher exploring this groundbreaking avenue.
Charles Nichols, PhD, Louisiana State University HSC School of Medicine, Associate Professor of Pharmacology
Fear & Flexibility: How Psilocybin Reshapes Cortical Serotonergic Brain Circuits After Trauma
Gregory Corder, PhD, University of Pennsylvania, Assistant Professor
